2seventy bio | 10-Q: FY2025 Q1 Revenue Beats Estimate at USD 22.94 M

2seventy bio | 8-K: FY2025 Q1 Revenue Beats Estimate at USD 22.94 M

2Seventy Bio IncQ) expected to post a loss of 17 cents a share - Earnings Preview

2Seventy Bio IncQ) is expected to report a loss of 17 cents per share and a 12.3% increase in quarterly revenue to $13.963 million for the period ending March 31, 2025. The average analyst rating is "hold" with no strong buy recommendations. The mean earnings estimate has decreased by 20.9% in the last three months, while the median 12-month price target is $5.00, slightly above the last closing price of $4.99.

Why Bristol-Myers Squibb Co. (BMY) Went Up On Friday?

Bristol-Myers Squibb Co. (BMY) saw its share price rise by 1.90% to $60.02 on Friday, following positive news from the European regulatory committee regarding its cancer treatment Opdivo. The Committee for Medicinal Products for Human Use recommended approval for Opdivo for adult solid tumors, with a decision from the European Commission expected by June 2, 2025. Additionally, BMY announced plans to acquire 2seventy Bio for $286 million, with the transaction anticipated to close in the second quarter, pending regulatory conditions.

2Seventy Bio Inc reports results for the quarter ended December 31 - Earnings Summary

2Seventy Bio IncQ) reported a quarterly adjusted loss of 37 cents per share for the quarter ended December 31, exceeding analyst expectations of a 26-cent loss. Revenue fell 72.6% to $2.93 million, significantly below the expected $12.29 million. The company incurred a total loss of $19.52 million. Despite the disappointing results, shares rose by 68.7% this quarter. Analysts maintain a "hold" rating, with a median 12-month price target of $5.00.